Boundless Bio, Inc.

NASDAQ:BOLD

Biotechnology

Healthcare
$2.40 +85.71%

+$1.20 today

Market cap
$56.67M
Beta
0.97
P/E (TTM)
-1.0
EPS (TTM)
-$2.50
52W Low $0.96High $2.75

Volume 0.15M

Average 0.22M

BOLD Financing Cash Flow

Net cash exchanged with lenders and shareholders through borrowing, repayments, buybacks, and dividends.

Boundless Bio, Inc.NASDAQ: BOLD

Financing Cash Flow · Q1 FY2026 · quarter ended Mar 2026

Financing cash flow outflow grows to $0

Q1 FY2026 financing cash flow was $0, compared with $0 a year earlier. Trailing-twelve-month financing cash flow was $141K. Over 3 fiscal years it compounded at +3.8% a year.

Context

  • Financing cash flow increased in 1 of the last 3 fiscal years.

What to watch

Whether quarterly financing cash flow holds near $0 or moves back toward the trailing-twelve-month quarterly average of $35.25K.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterMar 2026
$0-100.0% QoQ
Last fiscal yearDec 2025
$141K-99.8% YoY
LTMMar 2026
$141K-99.8% YoY
Financing Cash Flow past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter———
1 year-99.8%——
3-year CAGR+3.8%——
5-year CAGR——
10-year CAGR——

Financing Cash Flow history

USD · from the cash flow

Latest · FY2025
141K USD
Year-over-year change
-99.8%
4-year CAGR
-80.9%

Financing Cash Flow vs competitors

How BOLD compares with its peers on the latest reported figures

  • BOLD's LTM Mar 2026 financing cash flow of $141K is the 3rd largest of the 4 companies compared; the peer median is $5.67M.
  • Its year-over-year change of -99.8% is the lowest of 4, against a peer median of +234.8%.
  • Over three fiscal years its annual growth of +3.8% compares with a peer median of -90.7%.
BOLD Competitors Peer median
Financing Cash Flow for BOLD and competitors
Company Period LTM YoY 3-year CAGR% of revenue
ANTXAN2 Therapeutics, Inc.LTM Mar 2026$37.38M +42373.9%-88.3%—
QTTBQ32 Bio Inc.LTM Mar 2026$5.67M +234.8%—10.6%
BOLDBoundless Bio, Inc.LTM Mar 2026$141K -99.8%+3.8%—
RLYBRallybio CorporationLTM Mar 2026$19K -99.6%-93.2%2.2%
Peer median (excluding BOLD) $5.67M+234.8%-90.7%6.4%

Competitors are the stored peer set for BOLD. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income(25.21M)(45.9M)(49.43M)(65.36M)(58.2M)
Depreciation & Amortization682K942K957K1.09M1.25M
Deferred Income Tax00000
Stock-Based Compensation1.16M2.29M3.34M7.52M6.13M
Change in Working Capital(837K)866K(799K)(1.68M)3.46M
Accounts Receivables00000
Inventory00000
Accounts Payables01.91M0775K1.63M
Other Working Capital(837K)(1.05M)(799K)(2.45M)1.83M
Other Non-Cash Items959K2.21M(915K)(2.4M)698K
Operating Cash Flow(23.25M)(39.6M)(46.86M)(60.84M)(46.66M)
Capital Expenditures(2.03M)(1.07M)(633K)(2.54M)(546K)
Acquisitions (Net)00000
Purchases of Investments(77.49M)(42.6M)(160.12M)(208.47M)(174.9M)
Sales of Investments20.24M59.8M122.5M184.9M213.24M
Other Investing Activities00000
Investing Cash Flow(59.29M)16.13M(38.26M)(26.1M)37.8M
Debt Repayment00000
Common Stock Issued0126K093M141K
Common Stock Repurchased00000
Dividends Paid00000
Other Financing Activities208K0(1.77M)(3.18M)0
Financing Cash Flow105.53M126K97.9M89.82M141K
Effect of Forex Changes00000
Net Change in Cash22.99M(23.34M)12.78M2.88M(8.72M)
Free Cash Flow(25.28M)(40.66M)(47.49M)(63.38M)(47.21M)

Boundless Bio, Inc.

NASDAQ:BOLD

Intrinsic Alpha fair value

Locked

Current Price

$2.40

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.